Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Susceptibility of Methicillin-Resistant Staphylococcus aureus and Methicillin-Susceptible Staphylococcus aureus to a New Antimicrobial, Copper Silicate

Kerry C. Carson, Jessica G. Bartlett, Trina-Jean Tan, Thomas V. Riley
Kerry C. Carson
1Microbiology and Infectious Disease, PathWest Laboratory Medicine WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: k-carson@cyllene.uwa.edu.au
Jessica G. Bartlett
1Microbiology and Infectious Disease, PathWest Laboratory Medicine WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trina-Jean Tan
1Microbiology and Infectious Disease, PathWest Laboratory Medicine WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas V. Riley
1Microbiology and Infectious Disease, PathWest Laboratory Medicine WA
2Microbiology and Immunology, The University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia 6009, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00771-07
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The soluble copper silicate (CS) MIC of 100 strains of methicillin-resistant Staphylococcus aureus and 100 strains of methicillin-susceptible S. aureus (MSSA) was 175 mg Cu/liter. Bactericidal and postantibiotic effects (≥1 h) were seen at 2× MIC and 4× MIC. The frequency of mutation was <10−9, and serial passage could not extend growth beyond 1.6× MIC.

Staphylococcus aureus is a commensal bacterium and also a major human pathogen. It may be carried transiently on the skin or for several months in the mucus membranes of the nasal passages. People who persistently carry S. aureus are at an increased risk of subsequent infection (12). Topical antibiotics, such as mupirocin or neomycin, have been used to eliminate S. aureus carriage in high-risk groups of hospitalized patients (6, 13, 14).

In nature copper silicate (CS; chrysolla) is an insoluble, amorphous blue-green mineral found within copper ore bodies. A novel, solubilized form of CS has been developed by Convé PLC as a topical antimicrobial that contains 0.28% (wt/wt) as copper, or 2,800 mg Cu/liter. The CS solution used in this study was manufactured by Patheon Inc. (Toronto, Canada) on 12 December 2005.

The 200 isolates of S. aureus and S. aureus ATCC 29213 used were obtained from the PathWest Laboratory Medicine WA (Nedlands, Western Australia, Australia) culture collection of bacteria isolated from normally sterile anatomical sites. All clinical isolates were identified by microbiology staff at PathWest Laboratory Medicine WA using standard techniques.

The MIC was assayed in Mueller-Hinton broth (MHB) using the Clinical and Laboratory Standards Institute (CLSI) guidelines for susceptibility testing of aerobic bacteria by broth microdilution (3). The copper concentration was taken as the known amount of copper (wt/wt) in the CS solution and did not necessarily reflect the free copper ions available in the MHB. The MIC for CS was remarkably consistent, as all S. aureus strains, including the control strain, S. aureus ATCC 29213, had an MIC of 175 mg Cu/liter. In comparison, the copper sulfate MIC for 20 strains (10 methicillin-resistant S. aureus [MRSA] strains and 10 methicillin-susceptible S. aureus [MSSA] strains) was 1 dilution higher, at 350 mg Cu/liter. The minimal bactericidal concentration (MBC) of CS ranged from 175 to 700 mg Cu/liter, with a 50% MBC (MBC50) and MBC90 of 350 mg Cu/liter for both MRSA and MSSA. There was no evidence of a more resistant subgroup within the total population tested.

Time-kill kinetics showed that CS at the MIC was inhibitory. Bactericidal effects at 2× MIC were strain dependent, as only MRSA 101 was inhibited, while a total kill (99.9%) of S. aureus ATCC 29213 was achieved in 28 min (Fig. 1A and B). At 4× MIC, a total kill for both MRSA 101 and S. aureus ATCC 29213 occurred at 28 min and 10 min, respectively (Fig. 1A and B).

The capacity of CS to cause a postantibiotic effect (PAE) in MRSA 101, MRSA 102, and S. aureus ATCC 29213 was investigated. MRSA 102 was included, as it had a MBC of 700 mg Cu/liter, 1 dilution higher than that of MRSA 101 and S. aureus ATCC 29213. After a 30-min exposure to CS at the MIC, growth of MRSA 101 and MRSA 102 was unaffected. However, S. aureus ATCC 29213 had an extended lag phase of 2 to 2.5 h, and the time taken for the 10-fold increase was significantly different (P < 0.05) from the that for the control (Table 1). When exposed to 2× MIC, all three strains took a significantly longer time than the control to increase 10-fold (Table 1). The PAE was considered to be significant only when the corresponding time for the 10-fold increase in the viable count was significantly different from that for the control (P < 0.05). Therefore, a significant PAE was seen at the MIC with S. aureus ATCC 29213 and with all three strains at twice the MIC (Table 1).

Spontaneous-resistance studies with mupirocin have shown that S. aureus produces a small population of resistant mutants, with MICs of 1 to 4 mg/liter, at a frequency of 1 to 4 per 109 bacterial cells (2). In similar studies with CS at 2× MIC and 4× MIC, no resistant mutants were detected (Table 2). In serial-passage experiments to induce tolerance or resistance, a twofold increase in the MIC was recorded for two of nine phenotypically distinct isolates capable of growth at 275 mg Cu/liter (1.6× MIC). Nevertheless, this did not represent a significant change in susceptibility as it was less than a fourfold difference. Thus, it appears that tolerance or resistance to CS cannot be readily induced in S. aureus.

The most intensive study of copper homeostasis and resistance in gram-positive bacteria has been with the enterococci (7, 8, 15). Nothing is known of copper homoeostasis or resistance in S. aureus, though genomic sequencing has identified a putative copA gene in both MRSA and MSSA (5, 10, 13). The copper sulfate MIC range for Enterococcus hirae and Enterococcus faecium has been recorded at 127 to 508 mg Cu/liter (1, 9), a very similar result to that recorded for S. aureus in this study with CS. In enterococci, acquired copper resistance has been linked to a transferable plasmid that harbors the copper resistance operon (tcrYAZB), which increased the copper MIC sevenfold to 1,525 mg Cu/liter and also transferred resistance to tetracycline, kanamycin, and streptomycin, either singly or in combination with resistance to macrolides and glycopeptides (7, 9). The plasmid also carried the transposable element Tn1546 (8). S. aureus has acquired vancomycin resistance from an interspecies transfer of the Tn1546 element from Enterococcus faecalis (16), but the possibility of the tcrYAZB operon being transferred in such a manner is unknown.

Mupirocin is the current agent of choice for MRSA eradication in colonized patients and health care workers (11). Widespread clinical use of mupirocin has resulted in mutants with low (8 to 256 mg Cu/liter) and high (≥512 mg Cu/liter) levels of resistance; the increasing prevalence of these mutants gives impetus to the need to find alternative topical antimicrobials for the control of MRSA carriage (4).

CS has in vitro antimicrobial activity against of S. aureus, including MRSA. The data in this study suggest that topical formulations of this antimicrobial may be useful in nasal decolonization therapy and treatment of dermatological infections. Convé PLC has produced a topical cream formulation (0.22% Cu, wt/wt) that has been well tolerated by over 350 people in phase 1 studies. However, clinical trials would need to be conducted to see if these promising in vitro results are a true indication of the potential of CS.

(These results were presented at the joint meeting of the 17th European Congress of Clinical and Infectious Diseases and the 25th International Congress of Chemotherapy, Munich, Germany, 31 March to 3 April 2007.)

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Time-kill curves of CS in MHB over a 4-h period with MRSA 101 (A) and S. aureus ATCC 29213 (B) and concentrations at MIC, 2× MIC, and 4× MIC. ▪, growth control; 2MIC, 2× MIC; 4MIC, 4× MIC; dashed lines, total kill. The experiments were conducted a minimum of three times and the results normalized. The standard error of each data point is shown.

View this table:
  • View inline
  • View popup
TABLE 1.

Time for a 10-fold increase and the calculated PAE for MRSA 101, MRSA 102, and S. aureus ATCC 29213 after 30-min exposure to CSa

View this table:
  • View inline
  • View popup
TABLE 2.

Viable count and frequency of mutation of MRSA 101, MRSA 102, MSSA 1, and S. aureus ATCC 29213 with rifampin and CSa

ACKNOWLEDGMENTS

This research was fully funded by Convé Ltd., a subsidiary of Convé PLC in which K. C. Carson is a shareholder.

FOOTNOTES

    • Received 15 June 2007.
    • Returned for modification 12 July 2007.
    • Accepted 21 September 2007.
  • Copyright © 2007 American Society for Microbiology

REFERENCES

  1. 1.↵
    Aarestrup, F. M., and H. Hasman. 2004. Susceptibility of different bacterial species isolated from food animals to copper sulphate, zinc chloride and antimicrobial substances used for disinfection. Vet. Microbiol.100:83-89.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Casewell, M., and R. Hill. 1985. In vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother.15:523-531.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    CLSI. 2006. Performance standards for antimicrobial testing; 16th informational supplement (M100-S16). Clinical and Laboratory Standards Institute, Wayne, PA.
  4. 4.↵
    Deshpande, L. M., A. M. Fix, M. A. Pfaller, R. N. Jones, and the SENTRY Antimicrobial Surveillance Program Participants Group. 2002. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diag. Microbiol. Infect. Dis.42:283-290.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Diep, B. A., S. R. Gill, R. F. Chang, T. H. Phan, J. H. Chen, M. G. Davidson, F. Lin, J. Lin, H. A. Carleton, E. F. Mongodin, G. F. Sensabaugh, and F. Perdreau-Remington. 2006. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet367:731-739.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Farr, B. M. 2002. Mupirocin to prevent S. aureus infections. N. Engl. J. Med.346:1905-1906.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Hasman, H. 2005. The tcrB gene is part of the tcrYAZB operon conferring copper resistance in Enterococcus faecium and Enterococcus faecalis. Microbiology151:3019-3025.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Hasman, H., and F. M. Aarestrup. 2005. Relationship between copper, glycopeptide, and macrolide resistance among Enterococcus faecium strains isolated from pigs in Denmark between 1997 and 2003. Antimicrob. Agents Chemother.49:454-456.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Hasman, H., and F. M. Aarestrup. 2002. tcrB, a gene conferring transferable copper resistance in Enterococcus faecium: occurrence, transferability, and linkage to macrolide and glycopeptide resistance. Antimicrob. Agents Chemother.46:1410-1416.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    Holden, M. T. G., E. J. Feil, J. A. Lindsay, S. J. Peacock, N. P. J. Day, M. C. Enright, T. J. Foster, C. E. Moore, L. Hurst, R. Atkin, A. Barron, N. Bason, S. D. Bentley, C. Chillingworth, T. Chillingworth, C. Churcher, L. Clark, C. Corton, A. Cronin, J. Doggett, L. Dowd, T. Feltwell, Z. Hance, B. Harris, H. Hauser, S. Holroyd, K. Jagels, K. D. James, N. Lennard, A. Line, R. Mayes, S. Moule, K. Mungall, D. Ormond, M. A. Quail, E. Rabbinowitsch, K. Rutherford, M. Sanders, S. Sharp, M. Simmonds, K. Stevens, S. Whitehead, B. G. Barrell, B. G. Spratt, and J. Parkhill. 2004. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc. Natl. Acad. Sci. USA101:9786-9791.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Hurdle, J. G., A. J. O'Neill, and I. Chopra. 2005. Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob. Agents Chemther.49:4821-4833.
    OpenUrlFREE Full Text
  12. 12.↵
    Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev.10:505-520.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Kuroda, M., T. Ohta, I. Uchiyama, T. Baba, H. Yuzawa, I. Kobayashi, L. Cui, A. Oguchi, K.-I. Aoki, Y. Nagai, J. Lian, T. Ito, M. Kanamori, H. Matsumaru, A. Maruyama, H. Murakami, A. Hosoyama, Y. Mizutani-Ui, N. K. Takahashi, T. Sawano, R.-I. Inoue, C. Kaito, K. Sekimizu, H. Hirakawa, S. Kuhara, S. Goto, J. Yabuzaki, M. Kanehisa, A. Yamashita, K. Oshima, K. Furuya, C. Yoshino, T. Shiba, M. Hattori, N. Ogasawara, H. Hayashi, and K. Hiramatsu. 2001. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet357:1225-1240.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Lowy, F. 1998. Staphylococcus aureus infections. N. Engl. J. Med.339:520-532.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    Odermatt, A., H. Suter, R. Krapf, and M. Solioz. 1993. Primary structure of two P-type ATPases involved in copper homeostasis in Enterococcus hirae. J. Biol. Chem.268:12775-12779.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Weigel, L. M., D. B. Clewell, S. R. Gill, N. C. Clark, L. K. McDougal, S. E. Flannagan, J. F. Kolonay, J. Shetty, G. E. Killgore, and F. C. Tenover. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science301:1569-1571.
    OpenUrl
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Susceptibility of Methicillin-Resistant Staphylococcus aureus and Methicillin-Susceptible Staphylococcus aureus to a New Antimicrobial, Copper Silicate
Kerry C. Carson, Jessica G. Bartlett, Trina-Jean Tan, Thomas V. Riley
Antimicrobial Agents and Chemotherapy Nov 2007, 51 (12) 4505-4507; DOI: 10.1128/AAC.00771-07

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Susceptibility of Methicillin-Resistant Staphylococcus aureus and Methicillin-Susceptible Staphylococcus aureus to a New Antimicrobial, Copper Silicate
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Susceptibility of Methicillin-Resistant Staphylococcus aureus and Methicillin-Susceptible Staphylococcus aureus to a New Antimicrobial, Copper Silicate
Kerry C. Carson, Jessica G. Bartlett, Trina-Jean Tan, Thomas V. Riley
Antimicrobial Agents and Chemotherapy Nov 2007, 51 (12) 4505-4507; DOI: 10.1128/AAC.00771-07
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

copper
methicillin resistance
Silicates
Staphylococcus aureus

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596